E2F1 and neoplasm: The pooled results of all 17 studies conducted with tumor tissue showed that the increased expression of E2F1 was a favorable survival prognosis biomarker (HR = 1.21, 95%CI:1.16–1.26, I2 = 95.3%, *PHeterogeneity = 0.000) (Fig. 2).